Natpara and Ergocalciferol drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Natpara (parathyroid hormone) and Ergocalciferol (ergocalciferol). Common drug interactions include headache among females and hypocalcaemia among males.

The phase IV clinical study analyzes what interactions people have when they take Natpara and Ergocalciferol. It is created by eHealthMe based on reports of 58 people who take the same drugs from the FDA, and is updated regularly.

What is Natpara?

Natpara has active ingredients of parathyroid hormone. eHealthMe is studying from 4,488 Natpara users. Check the latest studies of Natpara.

What is Ergocalciferol?

Ergocalciferol has active ingredients of ergocalciferol. It is often used in rickets. eHealthMe is studying from 32,652 Ergocalciferol users. Check the latest studies of Ergocalciferol.

On Jul, 20, 2026

58 people who take Natpara and Ergocalciferol together, and have interactions are studied.

Natpara and Ergocalciferol drug interactions.

What are the common drug interactions of Natpara and Ergocalciferol, by gender? *:

female:

Headache (pain in head)
Hypoparathyroidism (inadequate secretion of parathyroid hormone resulting in abnormally low levels of calcium in the blood)
Nephrolithiasis (calculi in the kidneys)
Muscle spasms (muscle contraction)
Paraesthesia (sensation of tingling, tickling, prickling, pricking, or burning of a person's skin with no apparent long-term physical effect)
Hypoaesthesia (reduced sense of touch or sensation)
Blood parathyroid hormone decreased
Hospitalisation
Hydronephrosis (water inside the kidney)
Malabsorption (a state arising from abnormality in absorption of food nutrients across the gastrointestinal (gi) tract)

male:

Hypocalcaemia (levels of calcium in blood serum are abnormally low)
Fatigue (feeling of tiredness)
Malaise (a feeling of general discomfort or uneasiness)
Pain
Renal disorder (kidney disease)

What are the common drug interactions of Natpara and Ergocalciferol, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

Blood calcium decreased
Hypoaesthesia (reduced sense of touch or sensation)
Muscle spasms (muscle contraction)
Paraesthesia (sensation of tingling, tickling, prickling, pricking, or burning of a person's skin with no apparent long-term physical effect)

40-49:

Malaise (a feeling of general discomfort or uneasiness)
Injection site swelling
Hypocalcaemia (levels of calcium in blood serum are abnormally low)
Blood parathyroid hormone decreased
Thyroid cancer
Dysgeusia (disorder of the sense of taste)
Insomnia (sleeplessness)
Vomiting
Weight increased
Fatigue (feeling of tiredness)

50-59:

Hypocalcaemia (levels of calcium in blood serum are abnormally low)
Quality of life decreased
Blood calcium decreased
Hospitalisation
Ventricular tachycardia (rapid heartbeat that originates in one of the lower chambers (the ventricles) of the heart)
Calcium deficiency (lack of calcium)
Metastases to lung (cancer spreads to lung)
Metastases to lymph nodes (cancer spreads to lymph node)
Vitamin b12 deficiency

60+:

n/a

What are the existing conditions these people have? *

Hypoparathyroidism (inadequate secretion of parathyroid hormone resulting in abnormally low levels of calcium in the blood): 25 people, 43.10%
Hypocalcaemia (levels of calcium in blood serum are abnormally low): 16 people, 27.59%
Post Procedural Hypothyroidism: 4 people, 6.90%

* Approximation only. Some reports may have incomplete information.

Do you take Natpara and Ergocalciferol?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously